Fenbendazole. Mebendazole. Ivermectin.
They’re cheap, widely discussed online, and often described as “miracle” cancer treatments — but that’s not how real oncology works.
In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, breaks down when repurposed drugs actually make sense in cancer care — and when they don’t. Rather than hype or guesswork, this episode explains the biology, mechanisms, and molecular targets that determine whether these drugs help or fail.
Dr. Prato walks through how drugs like mebendazole and fenbendazole affect microtubules, angiogenesis, glycolysis, and immune signaling, and why ivermectin can influence cancer stem cells, resistance pathways, and metastatic signaling — but only when the patient’s molecular heat maps match those mechanisms.
You’ll learn why blindly taking off-label drugs often leads to disappointment, why these agents should never be used alone, and how deep multi-omics testing (DNA, RNA transcriptomics, immune spatial biology) identifies when these drugs become powerful adjuvants alongside precision chemotherapy, immunotherapy, cellular biologics, and metabolic support.
🎯 What You’ll Learn in This Episode:
• Why fenbendazole, mebendazole & ivermectin don’t work for everyone
• How microtubule disruption can be cytotoxic when targets are correct
• Which glycolytic and angiogenesis markers predict response
• Why ivermectin may help with cancer stem cells and drug resistance
• How RNA transcriptomics and immune spatial biology guide repurposed drug use
• Why repurposed drugs must be adjuvants — not standalone treatments
• How precision targeting turns “cheap drugs” into powerful tools
• Why long-term response requires matching mechanisms, not guessing
📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: https://www.envita.com/?utm_source=Dr...
📞 Speak with a care coordinator: 866-830-4576
Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
You can read the full peer-reviewed study at:
https://www.scirp.org/journal/paperinformation?paperid=132493
